ZBIO - Zenas Biopharma Inc.

18.01
-0.580   -3.220%

Share volume: 535,232
Last Updated: 04-28-2026
Pharmaceutical Products/Pharmaceutical Preparations: -0.12%

PREVIOUS CLOSE
CHG
CHG%
$18.59
-0.58
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
41%
Profitability 35%
Dept financing 25%
Liquidity 50%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-0.99%
1 Month
-1.18%
3 Months
-13.75%
6 Months
-35.70%
1 Year
60.80%
2 Year
-0.77%
Key data
Stock price
$18.01
P/E Ratio 
N/A
DAY RANGE
$17.68 - $19.16
EPS 
-$7.19
52 WEEK RANGE
$8.51 - $44.60
52 WEEK CHANGE
$55.53
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
57.361 M
DIVIDEND
$0.00
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
-0.02
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$458,690
AVERAGE 30 VOLUME 
$759,821
Company detail
CEO: Leon O. Moulder, Jr.
Region: US
Website: zenasbio.com
Employees: 0
IPO year: 2024
Issue type: Common Stock
Market: NASDAQ
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

We are a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies for patients in need. On August 2, 2023, the Company was domesticated as a Delaware corporation and, concurrent therewith, we changed our name from Zenas BioPharma (Cayman) Limited to Zenas BioPharma, Inc. Our principal executive offices are located at 1000 Winter Street, Suite 1200, Waltham, MA 02451.

Recent news